Pharmacists News Alerts

 
 
  • Alert FDA OKs Natesto, First-Ever Nasal Testosterone Treatment The new product reduces the risk for exposure to women and children and may offer greater convenience…or not.
  • Alert FDA Approves Weekly Injectable Albiglutide (Tanzeum) for T2D Albiglutide, to be marketed as Tanzeum, is a once-weekly injectable glucagonlike peptide 1 receptor agonist.
  • Alert HHS Secretary Kathleen Sebelius Resigns Kathleen Sebelius, the health and human services secretary, is resigning, ending her 5-year term that was marred by the problem-plagued rollout of the Affordable Care Act.
  • Alert FDA OKs Oralair, First US Sublingual Allergy Immunotherapy The FDA approved a sweet vernal, orchard, perennial rye, timothy, and Kentucky blue grass mixed pollens allergen extract tablet for sublingual use (Oralair, Stallergenes Inc) for grass pollen allergy.
  • Alert FDA Approves First ER Oxycodone Acetaminophen Combo The combination drug, formerly known as MNK-795, is approved for acute pain severe enough to require opioid treatment and for whom alternatives are ineffective.
  • Alert Adverse Events Reported With Medisca's L-Citrulline The FDA has alerted healthcare providers to adverse event reports associated with potentially subpotent L-citrulline that was repackaged and distributed by Medisca Inc.
  • Alert FDA Reviewing Saxagliptin Trial Data for Possible HF Risk The FDA issued a communication this morning stating it has requested the trial data from the manufacturer so that it can investigate a possible association between the use of saxagliptin and heart-failure risk.
  • Alert FDA Now Investigating CVD Risks With Testosterone Therapy The investigations emerges after two studies, including one published this week, highlight the risk of serious adverse cardiovascular events among men treated with the FDA-approved testosterone therapies.
  • Alert OTC Acne Products Make FDA Watch List Patients using topical products containing benzoyl peroxide and salicylic acid have experienced hypersensitivity and anaphylactic reactions. No causal link has yet been confirmed.
  • Alert FDA Asks Docs to Limit Acetaminophen in Prescription Meds Citing the risk for liver damage, the FDA asks healthcare providers to stop prescribing combination drug products that contain more than 325 mg of acetaminophen.
  • Alert Dextrose and Sodium Chloride IV Solutions Recalled Evidence of particulate matter has prompted Baxter to recall 795,000 individual units of 5% dextrose and 0.9% sodium chloride intravenous solutions.
  • Alert Lidocaine Injection Recalled in 28 States Hospira Inc has recalled a single lot of lidocaine HCI injection because of the presence of reddish-orange particles in glass vials; no adverse events have been reported to date.
  • Alert One Lot of HPV Vaccine Gardasil Recalled A small number of vials of Gardasil in lot number J007354 may contain glass particles in what federal health officials call an 'isolated' manufacturing incident.
  • Alert ADHD Meds Linked to Priapism, FDA Warns Methylphenidate has been linked to a rare risk for priapism in males taking the stimulant methylphenidate for the treatment of ADHD.
  • Alert Onfi Can Cause Serious Skin Reactions, FDA Warns Some patients taking the antiseizure drug have experienced Stevens-Johnson syndrome and toxic epidermal necrolysis, which can be fatal.
  • Alert World First Approval for Fenofibrate in Diabetic Retinopathy The established cholesterol-lowering drug fenofibrate has received first approval globally to slow the progression of diabetic retinopathy in patients with type 2 diabetes in Australia.
  • Alert FDA Issues Warning on Regadenoson, Adenosine Clinicians should avoid using these imaging agents for cardiac nuclear stress tests of patients with unstable angina or cardiovascular instability lest their odds of a fatal heart attack increase.
  • Alert FDA Sets Stage to Ban Trans Fats in Processed Foods The agency said it will give food manufacturers enough time to remove partially hydrogenated oil from their products if and when the ban becomes final.
  • Alert EU Recall of Some NovoMix 30 Insulin FlexPen and Penfill A very small percentage of some batches of the insulin medication NovoMix 30 FlexPen and Penfill are being recalled in the EU. Those with affected products should switch treatment, says the EMA.
  • Alert ACIP OKs Meningitis Vaccine (Menveo) for High-Risk Infants The CDC's Advisory Committee on Immunization Practices has recommended a meningococcal conjugate vaccine for infants and young toddlers at increased risk for meningococcal disease.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.